Table 3.

Association between duration and dose of statin use and gastric cancer risk (propensity score adjustment).

Statin useSHRa (95% CI)P valuePtrend
Nonstatin useRef (—)<0.001
<5 years0.46 (0.25–0.86)0.015
≥5 years0.43 (0.29–0.66)<0.001
Nonstatin useRef (—)
Statin use (for every 100 increase in cDDD)0.90 (0.81–0.99)0.037
  • aSHR was derived by PS adjustment after trimming of the extreme PS strata (5th and 95th percentiles).